title: Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization.
abstract: The objective of this study is to investigate pharmacokinetics of gelatin sponge microparticles (GSMs) combined with epirubicin in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization (TACE). Eighteen successful models of VX2 in New Zealand white rabbits was established, which were divided into three groups randomly: HAI group (n = 6), the epirubicin solution (epirubicin 10 mg mixed with saline 10 ml into the hepatic artery); GSMs-TACE group (n = 6), GSMs (20 mg) mixed with epirubicin solution (1 mg/ml); c-TACE group (n = 6), epirubicin (10 mg) mixed with lipiodol (10 ml). Each rabbit was administrated epirubicin at dose adjusted for a 1 mg/kg. Samples were collected from femoral vein at 5, 10, 20, 30, 40, 60, 90, and 120 min after therapy after 120 min; rabbit was killed, and tumor and peritumoral normal liver tissue was cised. Epirubicin concentrations in plasma and tumor were measured. The epirubicin concentration in plasma was significantly lower in GSMs-TACE group than in HAI group. C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively. The epirubicin concentration in tumor tissue was 53.06 ± 16.9 μg/g in c-TACE group, 44.49 ± 16.80 μg/g in the GSMs-TACE group, and 18.32 ± 8.30 μg/g in HAI group, respectively. Epirubicin concentration of GSMs-TACE group was significantly higher than that of HAI group (P < 0.05). The area under the curve (AUC) at 0-120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively. The AUC was lower in GSMs-TACE group than in HAI group (P < 0.05). Compared with HAI, GSMs-TACE has higher epirubicin concentrations in tumor and lower concentrations in plasma. The results show that GSMs-TACE has a feature of slow drug release-it may be one of the mechanisms of GSMs-TACE for HCC.
authors.affiliation: The First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning Province, China.
authors.forename: Yue Wei
authors.initials: YW
authors.lastname: Zhang
authors.forename: Jin
authors.initials: J
authors.lastname: Ao
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Ming Xi
authors.initials: MX
authors.lastname: Qiao
authors.forename: Xue Ling
authors.initials: XL
authors.lastname: Yang
authors.forename: Shun Xiong
authors.initials: SX
authors.lastname: Tang
authors.forename: Chuang
authors.initials: C
authors.lastname: Li
authors.forename: Ke
authors.initials: K
authors.lastname: Xu
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016461:Chemoembolization, Therapeutic; D002853:Chromatography, Liquid; D004337:Drug Carriers; D015251:Epirubicin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D005781:Gelatin Sponge, Absorbable / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006499:Hepatic Artery; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D011817:Rabbits; D053719:Tandem Mass Spectrometry
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D015251:Epirubicin
references.citation: Cancer Drug Deliv. 1987 Spring;4(1):55-61
references.pmid: 3300944
references.citation: World J Surg Oncol. 2013 Sep 09;11:222
references.pmid: 24016302
references.citation: J Vasc Interv Radiol. 1993 Nov-Dec;4(6):741-7
references.pmid: 8280994
references.citation: Eur J Cancer Clin Oncol. 1983 Aug;19(8):1053-65
references.pmid: 6311559
references.citation: Hepatology. 2003 Feb;37(2):429-42
references.pmid: 12540794
references.citation: Zhonghua Yi Xue Za Zhi. 2014 Mar 11;94(9):660-3
references.pmid: 24842203
references.citation: J Control Release. 2005 Mar 2;103(1):7-19
references.pmid: 15710496
references.citation: Zhonghua Gan Zang Bing Za Zhi. 2013 Aug;21(8):637-8
references.pmid: 24163874
references.citation: J Hepatol. 2007 Mar;46(3):474-81
references.pmid: 17239480
references.citation: Lancet. 2003 Dec 6;362(9399):1907-17
references.pmid: 14667750
references.citation: Onkologie. 2011;34(7):368-76
references.pmid: 21734423
references.citation: Cancer Res. 1993 Apr 1;53(7):1550-4
references.pmid: 8453622
references.citation: Cancer. 1992 Aug 1;70(3):585-90
references.pmid: 1320447
references.citation: Methods. 2009 Jun;48(2):125-38
references.pmid: 19328231
references.citation: Clin Cancer Res. 2006 Apr 15;12(8):2563-7
references.pmid: 16638866
references.citation: Radiology. 1983 May;147(2):401-5
references.pmid: 6300959
references.citation: Pharm Res. 1989 May;6(5):422-7
references.pmid: 2473465
references.citation: Hepatology. 2005 Nov;42(5):1208-36
references.pmid: 16250051
references.citation: J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):335-42
references.pmid: 16517780